**Name of Journal: *World Journal of Meta-Analysis***

**Manuscript NO: 32567**

**Manuscript Type: Minireviews**

**Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale**

Luchini C *et al*. Quality in meta-analyses

**Claudio Luchini, Brendon Stubbs, Marco Solmi, Nicola Veronese**

**Claudio Luchini,** Department of Pathology and Diagnostics, University and Hospital Trust of Verona, 37134 Verona, Italy

**Claudio Luchini,** Surgical Pathology Unit, Santa Chiara Hospital, 38122 Trento, Italy

**Brendon Stubbs,** Physiotherapy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ, United Kingdom

**Brendon Stubbs,** Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience King's College London, De Crespigny Park, London Box SE5 8AF, United Kingdom

**Brendon Stubbs,** Faculty of Health, Social Care and Education, Anglia Ruskin University, Chelmsford CM1 1SQ, United Kingdom

**Marco Solmi,** Department of Neurosciences, University of Padova, 35122 Padova, Italy

**Marco Solmi, Nicola Veronese,** Institute for clinical Research and Education in Medicine, IREM, 35122 Padova, Italy

**Nicola Veronese,** National Research Council, Neuroscience Institute, Aging Branch, 35131 Padova, Italy

**Author contributions:** Luchini C and Solmi M wrote the manuscript; Veronese N and Stubbs B critically evaluated the manuscript; all the authors approved the final form and the submission.

**Conflict-of-interest statement:** None to declare.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Claudio Luchini, MD,** Department of Diagnostics and Public Health University and Hospital Trust of Verona, 37134 Verona, Italy. [claudio.luchini@univr.it](mailto:claudio.luchini@univr.it)

**Telephone:**+39-45-8124842

**Fax:** +39-45-8027136

**Received:** January 13, 2017

**Peer-review started:** January 16, 2017

**First decision:** February 17, 2017

**Revised:** May 18, 2017

**Accepted:** June 6, 2017

**Article in press:**

**Published online:**

**Abstract**

One of the most important points in the meta-analyses is certainly represented by the assessment of the quality of the studies included in such research. The meta-analyses are considered the highest level of evidence in science. Also for this reason, the quality of the studies included should be accurately evaluated by standardized tools. The overall results of the meta-analysis depend indeed also on a rigorous evaluation of the studies quality. Among all the possible tools for this complex evaluation, the Newcastle-Ottawa Scale (NOS) is one of the most used worldwide, above all for observational studies. In this review, we will discuss the strengths and limitation of the NOS, also on the basis of the branch of science in which it has been applied.

**Key words:** Quality; Meta-analysis; Newcastle Ottawa Scale

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** To assess the quality of a meta-analysis is a remarkable point. In this review, we summarize the current evidence regarding the use of the Newcastle Ottawa Scale, one of the most used tool for evaluating quality in meta-analyses of observational studies.Taking also our works as example, we found that, even standardized and quick in its application, it suffers from some limitations, particularly when evaluating cross-sectional studies.

Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. *World J Meta-Anal* 2017; In press

**INTRODUCTION**

The quality assessment of studies included in systematic reviews and meta analyses is essential to enable a clear understanding of the evidence base. There are several sources of biases in meta-analyses including inaccurate selection of participants, data collection, analysis and selective reporting of study results[[1](#_ENREF_1)]. Many of these biases derive directly from the studies which are included in the meta-analysis. However, since systematic reviews and meta-analyses are considered the highest level of evidence in science[[2](#_ENREF_2)], the quality of the studies included should be accurately evaluated by validated and standardized tools.

For randomized controlled trials (RCTs), numerous tools are available to assess the risk of bias and methodological quality. Among the most commonly used, the Cochrane Collaboration’s tool[[3](#_ENREF_3)] seems one of the most accurate, since it accounts for the main features of the RCTs. However, other tools (such as the Jadad’s scale[[4](#_ENREF_4)]) are commonly used.

There are less methodological quality assessment tools available for the meta-analyses of observational studies. Some authors (including our group[[5](#_ENREF_5),[6](#_ENREF_6)]) have used reporting checklists for detailing the quality of included studies (such as STROBE[[7-9](#_ENREF_7)]). Whilst this method has several strengths, it may be seen as a simple reporting checklist. Such tools are not validated for assessing the quality of studies included in meta-analyses[[1](#_ENREF_1)]. For this reason, other tools are commonly used for assessing quality and risk of bias in observational (both cross-sectional and longitudinal) studies. Among these, the Newcastle-Ottawa Scale (NOS)[[10](#_ENREF_10)] is one of the most used worldwide.

Given the rising number of meta analyses of observational studies in the scientific literature, it is mandatory that the tools used to assess study quality in such endeavors are appraised. In this review, we will discuss the strengths and limitation of the NOS and its application, taking as example the branches of pathology and psychiatry, also with reference to some meta-analyses from our group of research.

**REVIEW AND DISCUSSION**

***Newcastle-Ottawa Scale: Definition***

The NOS can be used for both case-control and longitudinal (prospective studies). Typically, cross-sectional studies are evaluated as case control studies. The NOS evaluates three quality parameters (selection, comparability, and outcome) divided across eight specific items, which slightly differ when scoring case control and longitudinal studies[[10](#_ENREF_10)]. Each item on the scale is scored from one point, except for comparability, which can be adapted to the specific topic of interest to score up to two points. Thus, the maximum for each study is 9, with studies having less than 5 points being identified as representing at high risk of bias[[11](#_ENREF_11)].

In order to minimize the subjective interpretation of bias from scoring the NOS typically two independent authors should score each paper. However, in our opinion, the most important as well as critical point in the NOS scoring and filling in is certainly represented by the specific field in which the meta-analysis has been conducted. Each field of science has indeed intrinsic aspects with consequent implications: here we present these differences and both the advantages and the limitations of NOS scale in some of the most important branches of science.

***Newcastle-Ottawa Scale for meta-analyses in pathology***

The pathologists’ role in the era of modern medicine is based on performing an accurate as well as precise diagnosis, using standardized parameters, fixed cut-offs and thresholds. This standard strategy should be applied from the gross sampling to the pathology report[[12](#_ENREF_12),[13](#_ENREF_13)]. The perfect tool for modern surgical pathologists to reach a consensus on the parameters to be reported in the diagnosis (when, how and why) is certainly represented by meta-analysis. With this statistical method the best standard and significant parameters, that can guide the pathologists during the diagnostic activity, can be documented. The meta-analysis can be thus applied to three of the main aspects of surgical pathology: (1) the prognostic impact of the mutation status of particular genes in cancer[[14](#_ENREF_14),[15](#_ENREF_15)]; (2) the prognostic role of macro- or microscopic features of cancers[[16-25](#_ENREF_16)]; and (3) the diagnostic utility of some morphological, immunohistochemical and/or molecular parameters[[26](#_ENREF_26)]. Regarding the specific points of NOS scale for pathologists, an important topic is represented by the selection of the right method for ascertainment of exposure. If the meta-analysis regards a morphological aspect or an immunohistochemical staining, the classical microscopic exam should be preferred. Conversely, if the investigation regards a molecular aspect, the best standard molecular approach for the specific parameter should be applied, knowing that two of the most important are Sanger Sequencing[[27](#_ENREF_27)] and Next Generation Sequencing[[28-30](#_ENREF_28)]. For the outcome of interest, it is important specifying that this point is very subjective and may vary more than other points among different meta-analyses. In prognostic meta-analyses, however, we suggest to consider the disease-specific survival or the recurrence-free survival as the right parameter, being the overall survival the most common parameter in prognostic studies and thus not an index of quality. The point of NOS scale represented by the control for important factor or additional factor is obviously very important, since it can give two stars, determining a significant part of the quality’s evaluation. In this case the choice of the right parameters it is even more important. Knowing that data from multivariate analysis are more reliable, this merit should be acknowledge using this index, for example giving a star to a study that presents hazard ratios and an additional star if this data are obtained considering at least two or more potential confounders. For meta-analysis in pathology, at last, it has to be highlighted that a standard length for the follow-up of patients is 60 mo (5 years). A point of strength of this scale is that these parameters are not fixed and adaptable on the basis of the specific analysis. For example, a meta-analysis on the survival of patients with glioblastomas, a tumor with a very poor prognosis generally no longer than 2 years, will reach a star for smaller period (18 mo for example) than the classical 60 mo. The adaptability of NOS scale in this sense represents surely a point of strength. A limitation of this scale in pathology is that it may be very difficult, or even impossible, considering every possible source of bias in this scale, or highlighting every point of strength of the analyzed studies with this multi-stars system. The expertise and a consensus meeting among the authors is the best way to choose the right parameters for this scale.

***Newcastle-Ottawa Scale for meta-analyses in psychiatry***

Psychiatry is different from pathology and other branches of medicine, since diagnoses, response, and remission are defined exclusively on clinical evaluation. Thus, the selection and exposure or outcome NOS items, which assess whether cases are diagnosed through reliable and independent validation or through self-report instead, is fundamental in establishing research quality. Moreover, among the main diagnostic systems, namely DSM-V[[31](#_ENREF_31)] and ICD, some differences are evident[[32](#_ENREF_32)] and there remains a great debate about diagnosis in general. Also, a control group defined as free from a specific mental disease in the general population, has a lower odds of having other psychiatric comorbidity compared to a control population of in-patients, due to frequent medical comorbidity among patients with severe psychiatric conditions[[33](#_ENREF_33),[34](#_ENREF_34)]. Furthermore, remission and response definitions need specific psychopathologic scales’ cut-offs to be defined, and self-report or no description of such criteria need to be accounted for from a quality assessment scale, which is the case of NOS. Finally, treatment adherence is a substantial problem in psychiatry, and results are often affected by rates of completers and subjects lost at follow-up; again outcome NOS items account for such a variable. Thus authors encourage the use of NOS scale in the field of psychiatry, as has already been done in both observational[[35](#_ENREF_35),[36](#_ENREF_36)] and interventional[[37](#_ENREF_37)] studies’ meta-analyses.

***Strengths of the Newcastle-Ottawa Scale***

The NOS is one of the most known scale for assessing quality and risk of bias in observational studies for several reasons[[38](#_ENREF_38)], as reported in Table 1. The first one is that this tool is relatively quick to do, although it requires the right attention. Second, as already explained, the adaptability of its indexes on the basis of the investigated topic is very important. Furthermore, differently from other checklists and tools, it is validated for case-control and longitudinal studies.[[10](#_ENREF_10)] Finally, differently from other tools, NOS gives a score between 0 and 9 and so it is possible to use it as potential moderator in meta-regression analyses[[11](#_ENREF_11),[39](#_ENREF_39)].

***Weaknesses of the Newcastle-Ottawa Scale***

The NOS suffers from several weaknesses, however (Table 1). First, some domains are not univocal and one author should usually adapt this scale modifying some items. It is particularly true for cross-sectional studies for which the NOS should be adapted from the scheme of the case-control studies. Regarding the longitudinal investigations, the points usually adapted by the authors are the number and type of adjustments in the multivariate analyses, the duration of follow-up (not univocal follow-up is in fact given) and the outcome of interest not present at the baseline.

Another point of weakness is the low agreement between two independent reviewers in making the NOS. In the work proposed by Hartling et al., the agreement between the two reviewers was moderate/poor as shown by the k-value (< 0.50 for eight of the nine questions on the NOS)[[40](#_ENREF_40)]. This is particularly true in case of low experience by the authors in meta-analysis/systematic reviews[[41](#_ENREF_41)] suggesting that a training with a more expert author is needed.

Finally, the lack of comprehensive manuals could be interpreted as another limitation[[42](#_ENREF_42)].

**CONCLUSION**

The Newcastle-Ottawa Scale is a tool commonly used in medicine for the assessment of quality. Although it is a validated instrument and with a long history of reliability it suffers from several limitations. Other tools (tailored for cross-sectional studies and with more univocal items for other observational studies) are probably needed.

**REFERENCES**

1. **Dreier M**. Quality Assessment in Meta-analysis. In: Doi SAR, Williams GM, editors. Methods of Clinical Epidemiology. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013: 213-228
2. **Burns PB**, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. *Plast Reconstr Surg* 2011; **128**: 305-310 [PMID: 21701348 DOI: 10.1097/PRS.0b013e318219c171]
3. **Higgins JP**, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011; **343**: d5928 [PMID: 22008217 DOI: 10.1136/bmj.d5928]
4. **Jadad AR**, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996; **17**: 1-12 [PMID: 8721797]
5. **Solmi M**, Veronese N, Correll CU, Favaro A, Santonastaso P, Caregaro L, Vancampfort D, Luchini C, De Hert M, Stubbs B. Bone mineral density, osteoporosis, and fractures among people with eating disorders: a systematic review and meta-analysis. *Acta Psychiatr Scand* 2016; **133**: 341-351 [PMID: 26763350 DOI: 10.1111/acps.12556]
6. **Veronese N**, Bano G, Bertozzo G, Granziera S, Solmi M, Manzato E, Sergi G, Cohen AT, Correll CU. Vitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis. *J Thromb Haemost* 2015; **13**: 1665-1675 [PMID: 26179400 DOI: 10.1111/jth.13052]
7. **von Elm E**, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008; **61**: 344-349 [PMID: 18313558 DOI: 10.1016/j.jclinepi.2007.11.008]
8. **Solmi M**, Veronese N, Sergi G, Luchini C, Favaro A, Santonastaso P, Vancampfort D, Correll CU, Ussher M, Thapa-Chhetri N, Fornaro M, Stubbs B. The association between smoking prevalence and eating disorders: a systematic review and meta-analysis. *Addiction* 2016; **111**: 1914-1922 [PMID: 27206671 DOI: 10.1111/add.13457]
9. **Solmi M**, Veronese N, Favaro A, Santonastaso P, Manzato E, Sergi G, Correll CU. Inflammatory cytokines and anorexia nervosa: A meta-analysis of cross-sectional and longitudinal studies. *Psychoneuroendocrinology* 2015; **51**: 237-252 [PMID: 25462897 DOI: 10.1016/j.psyneuen.2014.09.031]
10. **Wells GA**, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses, 2012. Available from: URL: http: //wwwohrica/programs/clinical\_epidemiology/oxfordasp
11. **Veronese N**, Cereda E, Solmi M, Fowler SA, Manzato E, Maggi S, Manu P, Abe E, Hayashi K, Allard JP, Arendt BM, Beck A, Chan M, Audrey YJ, Lin WY, Hsu HS, Lin CC, Diekmann R, Kimyagarov S, Miller M, Cameron ID, Pitkälä KH, Lee J, Woo J, Nakamura K, Smiley D, Umpierrez G, Rondanelli M, Sund-Levander M, Valentini L, Schindler K, Törmä J, Volpato S, Zuliani G, Wong M, Lok K, Kane JM, Sergi G, Correll CU. Inverse relationship between body mass index and mortality in older nursing home residents: a meta-analysis of 19,538 elderly subjects. *Obes Rev* 2015; **16**: 1001-1015 [PMID: 26252230 DOI: 10.1111/obr.12309]
12. **Luchini C**, Parcesepe P, Nottegar A, Parolini C, Mafficini A, Remo A, Chilosi M, Manfrin E. CD71 in Gestational Pathology: A Versatile Immunohistochemical Marker With New Possible Applications. *Appl Immunohistochem Mol Morphol* 2016; **24**: 215-220 [PMID: 25906120 DOI: 10.1097/PAI.0000000000000175]
13. **Luchini C**, Parcesepe P, Mafficini A, Nottegar A, Parolini C, Veronese N, Remo A, Manfrin E. Specific expression patterns of epithelial to mesenchymal transition factors in gestational molar disease. *Placenta* 2015; **36**: 1318-1324 [PMID: 26459371 DOI: 10.1016/j.placenta.2015.09.012]
14. **Luchini C**, Veronese N, Solmi M, Cho H, Kim JH, Chou A, Gill AJ, Faraj SF, Chaux A, Netto GJ, Nakayama K, Kyo S, Lee SY, Kim DW, Yousef GM, Scorilas A, Nelson GS, Köbel M, Kalloger SE, Schaeffer DF, Yan HB, Liu F, Yokoyama Y, Zhang X, Pang D, Lichner Z, Sergi G, Manzato E, Capelli P, Wood LD, Scarpa A, Correll CU. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. *Oncotarget* 2015; **6**: 39088-39097 [PMID: 26384299 DOI: 10.18632/oncotarget.5142]
15. **Luchini C**, Veronese N, Yachida S, Cheng L, Nottegar A, Stubbs B, Solmi M, Capelli P, Pea A, Barbareschi M, Fassan M, Wood LD, Scarpa A. Different Prognostic Roles Of Tumor Suppressor Gene BAP1 In Cancer: A Systematic Review With Meta-Analysis. Genes, chromosomes & cancer 2016 [PMID: 27223342 DOI: 10.1002/gcc.22381]
16. **Luchini C**, Nottegar A, Pea A, Solmi M, Stubbs B, Capelli P, Sergi G, Manzato E, Fassan M, Wood LD, Scarpa A, Veronese N. Significance of the prognostic stratification of extranodal extension in colorectal cancer. *Ann Oncol* 2016; **27**: 1647 [PMID: 27069013 DOI: 10.1093/annonc/mdw173]
17. **Luchini C**, Nottegar A, Pea A, Solmi M, Stubbs B, Capelli P, Sergi G, Manzato E, Fassan M, Wood LD, Scarpa A, Veronese N. Extranodal extension is an important prognostic parameter for both colonic and rectal cancer. *Ann Oncol* 2016; **27**: 955-956 [PMID: 26802150 DOI: 10.1093/annonc/mdw034]
18. **Luchini C**, Nottegar A, Solmi M, Sergi G, Manzato E, Capelli P, Scarpa A, Veronese N. Prognostic implications of extranodal extension in node-positive squamous cell carcinoma of the vulva: A systematic review and meta-analysis. *Surgical Oncology* 2016; **25**: 60-65 [PMID: 26394825 DOI: 10.1016/j.suronc.2015.09.005]
19. **Luchini C**, Veronese N, Pea A, Sergi G, Manzato E, Nottegar A, Solmi M, Capelli P, Scarpa A. Extranodal extension in N1-adenocarcinoma of the pancreas and papilla of Vater: a systematic review and meta-analysis of its prognostic significance. *Eur J Gastroenterol Hepatol* 2016; **28**: 205-209 [PMID: 26566063 DOI: 10.1097/MEG.0000000000000520]
20. **Luchini C**, Wood LD, Cheng L, Nottegar A, Stubbs B, Solmi M, Capelli P, Pea A, Sergi G, Manzato E, Fassan M, Bagante F, Bollschweiler E, Giacopuzzi S, Kaneko T, de Manzoni G, Barbareschi M, Scarpa A, Veronese N. Extranodal extension of lymph node metastasis is a marker of poor prognosis in oesophageal cancer: a systematic review with meta-analysis. *J Clin Pathol* 2016 Jul 7, pii: jclinpath-2016-203830 [PMID: 27387986 DOI: 10.1136/jclinpath-2016-203830]
21. **Nottegar A**, Veronese N, Senthil M, Roumen RM, Stubbs B, Choi AH, Verheuvel NC, Solmi M, Pea A, Capelli P, Fassan M, Sergi G, Manzato E, Maruzzo M, Bagante F, Koç M, Eryilmaz MA, Bria E, Carbognin L, Bonetti F, Barbareschi M, Luchini C. Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis. *Eur J Surg Oncol* 2016; **42**: 919-925 [PMID: 27005805 DOI: 10.1016/j.ejso.2016.02.259]
22. **Veronese N**, Fassan M, Wood LD, Stubbs B, Solmi M, Capelli P, Pea A, Nottegar A, Sergi G, Manzato E, Carraro S, Maruzzo M, Cataldo I, Bagante F, Barbareschi M, Cheng L, Bencivenga M, de Manzoni G, Luchini C. Extranodal Extension of Nodal Metastases Is a Poor Prognostic Indicator in Gastric Cancer: a Systematic Review and Meta-analysis. *J Gastrointest Surg* 2016; **20**: 1692-1698 [PMID: 27412320 DOI: 10.1007/s11605-016-3199-7]
23. **Veronese N**, Luchini C, Nottegar A, Kaneko T, Sergi G, Manzato E, Solmi M, Scarpa A. Prognostic impact of extra-nodal extension in thyroid cancer: A meta-analysis. *J Surg Oncol* 2015; **112**: 828-833 [PMID: 26493240 DOI: 10.1002/jso.24070]
24. **Veronese N**, Nottegar A, Pea A, Solmi M, Stubbs B, Capelli P, Sergi G, Manzato E, Fassan M, Wood LD, Scarpa A, Luchini C. Prognostic impact and implications of extracapsular lymph node involvement in colorectal cancer: a systematic review with meta-analysis. *Ann Oncol* 2016; **27**: 42-48 [PMID: 26483050 DOI: 10.1093/annonc/mdv494]
25. **Nottegar A**, Veronese N, Solmi M, Luchini C. Tumor suppressor gene ARID1A in cancer: recent advances and future perspective. *J Carinog Mutagene* 2016; **7**: 255 [DOI: 10.4172/2157-2518.100255]
26. **Luchini C**, Nottegar A, Solmi M, Veronese N. Meta-Analysis in Pathology. *J Pathol & Microbiol* 2016; **1**: 1002-1003
27. **Simbolo M**, Mafficini A, Agostini M, Pedrazzani C, Bedin C, Urso ED, Nitti D, Turri G, Scardoni M, Fassan M, Scarpa A. Next-generation sequencing for genetic testing of familial colorectal cancer syndromes. *Hered Cancer Clin Pract* 2015; **13**: 18 [PMID: 26300997 DOI: 10.1186/s13053-015-0039-9]
28. **Mafficini A**, Simbolo M, Parisi A, Rusev B, Luchini C, Cataldo I, Piazzola E, Sperandio N, Turri G, Franchi M, Tortora G, Bovo C, Lawlor RT, Scarpa A. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. *Oncotarget* 2016; **7**: 1076-1083 [PMID: 26745875 DOI: 10.18632/oncotarget.6834]
29. **Yachida S**, Wood LD, Suzuki M, Takai E, Totoki Y, Kato M, Luchini C, Arai Y, Nakamura H, Hama N, Elzawahry A, Hosoda F, Shirota T, Morimoto N, Hori K, Funazaki J, Tanaka H, Morizane C, Okusaka T, Nara S, Shimada K, Hiraoka N, Taniguchi H, Higuchi R, Oshima M, Okano K, Hirono S, Mizuma M, Arihiro K, Yamamoto M, Unno M, Yamaue H, Weiss MJ, Wolfgang CL, Furukawa T, Nakagama H, Vogelstein B, Kiyono T, Hruban RH, Shibata T. Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. *Cancer Cell* 2016; **29**: 229-240 [PMID: 26806338 DOI: 10.1016/j.ccell.2015.12.012]
30. **Luchini C**, Capelli P, Fassan M, Simbolo M, Mafficini A, Pedica F, Ruzzenente A, Guglielmi A, Corbo V, Scarpa A. Next-generation histopathologic diagnosis: a lesson from a hepatic carcinosarcoma. *J Clin Oncol* 2014; **32**: e63-e66 [PMID: 24493719 DOI: 10.1200/JCO.2012.47.5855]
31. **Chan CB**, Abe M, Hashimoto N, Hao C, Ifor R, Brewster AS, Wang G, Yu X, William B, Brewster AS, Wang G, Yu X, William B, Tjajadi M, Klein MG, Chen XS. Correction for Chan et al., Mice lacking asparaginyl endopeptidase develop disorders resembling hemophagocytic syndrome. *Proc Natl Acad Sci USA* 2009; **106**: 6023 [DOI: [10.1073/pnas.0901254106](http://dx.doi.org/10.1073%2Fpnas.0901254106" \t "pmc_ext)]
32. **Hyland P**, Shevlin M, McNally S, Murphy J, Hansen M, Elklit A. Exploring differences between the ICD-11 and DSM-5 models of PTSD: Does it matter which model is used? *J Anxiety Disord* 2016; **37**: 48-53 [PMID: 26618238 DOI: 10.1016/j.janxdis.2015.11.002]
33. **Vancampfort D**, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. *World Psychiatry* 2015; **14**: 339-347 [PMID: 26407790 DOI: 10.1002/wps.20252]
34. **Stubbs B**, Vancampfort D, De Hert M, Mitchell AJ. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. *Acta Psychiatr Scand* 2015; **132**: 144-157 [PMID: 25943829 DOI: 10.1111/acps.12439]
35. **Zaninotto L**, Solmi M, Toffanin T, Veronese N, Cloninger CR, Correll CU. A meta-analysis of temperament and character dimensions in patients with mood disorders: Comparison to healthy controls and unaffected siblings. *J Affect Disord* 2016; **194**: 84-97 [PMID: 26803780 DOI: 10.1016/j.jad.2015.12.077]
36. **Solmi M**, Zaninotto L, Toffanin T, Veronese N, Lin K, Stubbs B, Fornaro M, Correll CU. A comparative meta-analysis of TEMPS scores across mood disorder patients, their first-degree relatives, healthy controls, and other psychiatric disorders. *J Affect Disord* 2016; **196**: 32-46 [PMID: 26897455 DOI: 10.1016/j.jad.2016.02.013]
37. **Fornaro M**, Stubbs B, De Berardis D, Perna G, Valchera A, Veronese N, Solmi M, Ganança L. Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placebo-Controlled Clinical Trials. *Int J Mol Sci* 2016; **17**: 241 [PMID: 26891297 DOI: 10.3390/ijms17020241]
38. **Stang A**. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; **25**: 603-605 [PMID: 20652370 DOI: 10.1007/s10654-010-9491-z]
39. **Veronese N**, Carraro S, Bano G, Trevisan C, Solmi M, Luchini C, Manzato E, Caccialanza R, Sergi G, Nicetto D, Cereda E. Hyperuricemia protects against low bone mineral density, osteoporosis and fractures: a systematic review and meta-analysis. *Eur J Clin Invest* 2016; **46**: 920-930 [PMID: 27636234 DOI: 10.1111/eci.12677]
40. **Hartling L**, Hamm M, Milne A, Vandermeer B, Santaguida PL, Ansari M, Tsertsvadze A, Hempel S, Shekelle P, Dryden DM. Validity and Inter-Rater Reliability Testing of Quality Assessment Instruments. Rockville (MD): [Agency for Healthcare Research and Quality (US)](http://effectivehealthcare.ahrq.gov/); 2012 Mar, Report No.: 12-EHC039-EF [PMID: 22536612]
41. **Oremus M**, Oremus C, Hall GB, McKinnon MC. Inter-rater and test-retest reliability of quality assessments by novice student raters using the Jadad and Newcastle-Ottawa Scales. *BMJ Open* 2012; **2**: pii: e001368 [PMID: 22855629 DOI: 10.1136/bmjopen-2012-001368]
42. **Sterne JA**, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016; **355**: i4919 [PMID: 27733354 DOI: 10.1136/bmj.i4919]

**P-Reviewer:** Francisco G, Treglia G **S-Editor:** Kong JX **L-Editor: E-Editor:**

**Specialty type:** Medicine, research and experimental

**Country of origin:** Italy

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Strengths and weaknesses of the Newcastle-Ottawa Scale**

|  |  |
| --- | --- |
| **Strengths** | **Weaknesses** |
| Quick and adaptable | Not validation for cross-sectional studies |
| Validated | Poor agreement |
| Moderator | Lack of comprehensive manuals |